BeiGene Looks Overseas As It Progresses BTK Inhibitor
This article was originally published in PharmAsia News
Executive Summary
Chinese venture BeiGene is preparing to begin a clinical development program in the U.S. with a novel oncology drug, marking progress both for the company’s growing R&D capabilities and for its longer term ambitions in major international markets, which it sees as important to its future along with China.